Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Cash from Financing Activities (2010 - 2020)

Grifols' (GRFS) quarterly Cash from Financing Activities came in at -$121.5 million in Q1 2020, down 93.07% YoY from -$1.8 billion in Q2 2019, and up 54.2% on a QoQ basis from -$265.2 million in Q4 2019.

Grifols (GRFS) Cash from Financing Activities (2010 - 2020) Analysis & Trends

Grifols (GRFS) has 11 years of Cash from Financing Activities data on file, last reported at -$121.5 million in Q1 2020.

  • Quarterly Cash from Financing Activities fell 93.07% year-over-year to -$121.5 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was -$356.2 million (down 120.86% YoY) and the FY2025 annual result came in at -$615.8 million, up 57.6% from the prior year.
  • Cash from Financing Activities improved to -$121.5 million in Q1 2020, from -$265.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.8 billion in Q4 2017 to a low of -$265.2 million in Q4 2019.
  • A 5-year average of $236.6 million and a median of -$62.9 million in 2019 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2017 — Cash from Financing Activities jumped 1301.8% — and 2019, when it tumbled 503.89%.
  • Tracing GRFS's Cash from Financing Activities over 5 years: stood at -$146.6 million in 2016, then soared by 1301.8% to $1.8 billion in 2017, then slumped by 94.7% to $93.4 million in 2018, then slumped by 383.88% to -$265.2 million in 2019, then soared by 54.2% to -$121.5 million in 2020.
  • The last three Cash from Financing Activities figures came in at -$121.5 million (Q1 2020), -$265.2 million (Q4 2019), and -$62.9 million (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -8.78 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -5.05 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -3.89 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 2.34 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -3.66 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -
10 Grifols 5.45 Bn 4.45 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2020 -121.48 Mn
Mar 31, 2020 -121.48 Mn
Dec 31, 2019 -265.22 Mn
Dec 31, 2019 -265.22 Mn
Mar 31, 2019 -62.92 Mn
Mar 31, 2019 -62.92 Mn
Dec 31, 2018 93.43 Mn
Dec 31, 2018 93.43 Mn
Jun 30, 2018 -207.36 Mn
Jun 30, 2018 -207.36 Mn
Mar 31, 2018 15.58 Mn
Mar 31, 2018 15.58 Mn
Dec 31, 2017 1.76 Bn
Dec 31, 2017 1.76 Bn
Jun 30, 2017 -97.45 Mn
Jun 30, 2017 -97.45 Mn
Mar 31, 2017 1.67 Bn
Mar 31, 2017 1.67 Bn
Dec 31, 2016 -146.57 Mn
Dec 31, 2016 -146.57 Mn